{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T05:24:18Z","timestamp":1741238658968,"version":"3.38.0"},"reference-count":27,"publisher":"JLE","issue":"1","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.nephro.2018.08.003","type":"journal-article","created":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T01:36:39Z","timestamp":1547170599000},"page":"29-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effets \u00e0 court terme de l\u2019oxyhydroxyde sucroferrique chez les patients h\u00e9modialys\u00e9s\u00a0: exp\u00e9rience de NephroCare France"],"prefix":"10.1684","volume":"15","author":[{"given":"Charles","family":"Chazot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baya","family":"Fadel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mimi","family":"Kareche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Puyoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Jean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18929","reference":[{"key":"10.1016\/j.nephro.2018.08.003_bib0140","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1053\/j.ajkd.2008.03.020","article-title":"Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the dialysis outcomes and practice patterns Study (DOPPS)","volume":"52","author":"Tentori","year":"2008","journal-title":"Am J Kidney Dis"},{"year":"2017","series-title":"Rapport REIN 2015","author":"REIN.R.","key":"10.1016\/j.nephro.2018.08.003_bib0145"},{"key":"10.1016\/j.nephro.2018.08.003_bib0150","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1093\/ndt\/gfs418","article-title":"COSMOS: the dialysis scenario of CKD-MBD in Europe","volume":"28","author":"Fernandez-Martin","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2018.08.003_bib0155","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1053\/j.ajkd.2011.12.025","article-title":"Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status","volume":"60","author":"Lopes","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2018.08.003_bib0160","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.nephro.2015.11.005","article-title":"Changes in mineral and bone disorder management in a French cohort of hemodialysis patients between 2008\u00a0and 2012: The national bone and mineral metabolism observatory (Photo-Graphe 2\u00a0and 3)","volume":"12","author":"Pelletier","year":"2016","journal-title":"Nephrol Ther"},{"key":"10.1016\/j.nephro.2018.08.003_bib0165","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)","volume":"76","author":"Moe","year":"2009","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.nephro.2018.08.003_bib0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","article-title":"KDIGO 2017. Clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)","volume":"7","author":"Kidney Disease Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group","year":"2017","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.nephro.2018.08.003_bib0175","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0140-6736(13)60897-1","article-title":"Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis","volume":"382","author":"Jamal","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.nephro.2018.08.003_bib0180","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1053\/j.ajkd.2016.05.015","article-title":"Phosphate-binding agents in adults with CKD: A network meta-analysis of randomized trials","volume":"68","author":"Palmer","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2018.08.003_bib0185","doi-asserted-by":"crossref","first-page":"e0156891","DOI":"10.1371\/journal.pone.0156891","article-title":"Comparative effectiveness of phosphate binders in patients with chronic kidney disease: A systematic review and network meta-analysis","volume":"11","author":"Sekercioglu","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.nephro.2018.08.003_bib0190","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.nephro.2014.06.002","article-title":"[Another story of sevelamer]","volume":"10","author":"Jean","year":"2014","journal-title":"Nephrol Ther"},{"key":"10.1016\/j.nephro.2018.08.003_bib0195","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1056\/NEJM198504113121504","article-title":"Response to a physiologic dose of pyridoxine in type\u00a0I primary hyperoxaluria","volume":"312","author":"Yendt","year":"1985","journal-title":"New Engl J Med"},{"key":"10.1016\/j.nephro.2018.08.003_bib0200","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/ki.2014.58","article-title":"A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients","volume":"86","author":"Floege","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2018.08.003_bib0205","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ekir.2017.10.003","article-title":"Efficacy and safety of sucroferric oxyhydroxide and calcium carbonate in hemodialysis patients","volume":"3","author":"Koiwa","year":"2018","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.nephro.2018.08.003_bib0210","doi-asserted-by":"crossref","first-page":"59","DOI":"10.5414\/CN109021","article-title":"Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: A retrospective analysis of pharmacy data","volume":"88","author":"Coyne","year":"2017","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.nephro.2018.08.003_bib0215","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1093\/ndt\/gfw460","article-title":"One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis","volume":"32","author":"Floege","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2018.08.003_bib0220","doi-asserted-by":"crossref","DOI":"10.1177\/0148607117715440","article-title":"Comparative efficacy and safety of phosphate binders in hyperphosphatemia patients with chronic kidney disease","author":"Yang","year":"2017","journal-title":"J Parenter Enteral Nutr"},{"key":"10.1016\/j.nephro.2018.08.003_bib0225","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s40273-015-0320-9","article-title":"Cost effectiveness of sucroferric oxyhydroxide compared with sevelamer carbonate in the treatment of hyperphosphataemia in patients receiving dialysis, from the perspective of the National sealth service in Scotland","volume":"33","author":"Gutzwiller","year":"2015","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.nephro.2018.08.003_bib0230","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1093\/ndt\/gfv006","article-title":"Sucroferric Oxyhydroxide Study G. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients","volume":"30","author":"Floege","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2018.08.003_bib0235","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1159\/000447600","article-title":"Pharmacodynamic effects of sucroferric oxyhydroxide and sevelamer carbonate on vitamin\u00a0D receptor agonist bioactivity in dialysis patients","volume":"44","author":"Sprague","year":"2016","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.nephro.2018.08.003_bib0240","doi-asserted-by":"crossref","first-page":"4","DOI":"10.5414\/CNP74004","article-title":"PA21: a novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease","volume":"74","author":"Geisser","year":"2010","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.nephro.2018.08.003_bib0245","first-page":"1330","article-title":"Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide","volume":"32","author":"Covic","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2018.08.003_bib0250","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1053\/j.jrn.2017.02.007","article-title":"Long-term assessment of the safety and efficacy of PA21 (sucroferric oxyhydroxide) in Japanese hemodialysis patients with hyperphosphatemia: an open-label, multicenter, phase III study","volume":"27","author":"Koiwa","year":"2017","journal-title":"J Ren Nutr"},{"year":"2015","series-title":"Direction de l\u2019\u00e9valuation m\u00e9dicale, EedSP, Commission de la Transparence, Velphoro","author":"Haute Autorit\u00e9 de sant\u00e9 (HAS)","key":"10.1016\/j.nephro.2018.08.003_bib0255"},{"key":"10.1016\/j.nephro.2018.08.003_bib0260","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1016\/j.nephro.2017.01.004","article-title":"Sucroferric oxyhydroxide, a novel iron-based phosphate binder. Which current use in dialysis patients?","volume":"13(Suppl\u00a01)","author":"Bataille","year":"2017","journal-title":"Nephrol Ther"},{"key":"10.1016\/j.nephro.2018.08.003_bib0265","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/nep.12891","article-title":"Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: a randomized, open-label, multicentre, 12-week phase\u00a0III study","volume":"22","author":"Koiwa","year":"2017","journal-title":"Nephrology (Carlton, Vic)"},{"key":"10.1016\/j.nephro.2018.08.003_bib0135","article-title":"Evaluating the real-world safety and effectiveness of sucroferric oxyhydroxide in dialysis patients: An interim analysis of the VERIFIE study: kidney week","author":"Vervloet","year":"2017","journal-title":"Nex Orleans"}],"container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725518306175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725518306175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.jle.com\/10.1016\/j.nephro.2018.08.003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T16:17:29Z","timestamp":1741191449000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1769725518306175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S1769725518306175"],"URL":"https:\/\/doi.org\/10.1016\/j.nephro.2018.08.003","relation":{},"ISSN":["1769-7255"],"issn-type":[{"type":"print","value":"1769-7255"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effets \u00e0 court terme de l\u2019oxyhydroxyde sucroferrique chez les patients h\u00e9modialys\u00e9s\u00a0: exp\u00e9rience de NephroCare France","name":"articletitle","label":"Article Title"},{"value":"N\u00e9phrologie & Th\u00e9rapeutique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nephro.2018.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Soci\u00e9t\u00e9 francophone de n\u00e9phrologie, dialyse et transplantation. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}